



FOR IMMEDIATE RELEASE

Contact: William Wood, CEO
P.O. Box 7376, Ann Arbor MI 48107
Phone: (734) 649-1491

Life Magnetix, Inc. Adds Jeffrey S. Williams to its Board of Directors

ANN ARBOR, MI, December 2, 2010 - Life Magnetix, Inc., a spin-out from the University of Michigan engaged in the development of novel *in vitro* diagnostic tests, today announced the addition of Jeffrey S. Williams to its Board of Directors. Mr. Williams is currently President and CEO of Accuri Cytometers, Inc (Ann Arbor, MI). Before that, Jeff was President and CEO of HandyLab, Inc. (Ann Arbor, MI), where he led the growth and venture financing of the company, ultimately resulting in a sale to Becton, Dickinson & Company for \$275 million in November 2009. He was previously President and CEO of Genomic Solutions Inc., an Ann Arbor-based life science products company he co-founded in 1997. Mr. Williams led Genomic Solutions through a period of rapid growth culminating in an IPO on NASDAQ in 2000 and merger with Harvard Biosciences, Inc. in late 2002.

Jeff joins current board members Jan Garfinkle (Managing Director, Arboretum Ventures), George Dunbar (Venture Partner, Arboretum Ventures), Brandon McNaughton Ph.D. (Life Magnetix Founder and Chief Technical Officer) and William Wood (Life Magnetix Chief Executive Officer).

As noted by Ms. Garfinkle, "We are extremely pleased to have Jeff join our board. He brings the successful experience and valuable knowledge that a young company like Life Magnetix needs during this exciting period of technology advancement and product development. With the addition of Jeff, we have an outstanding Board of Directors, one that will provide the guidance necessary to help ensure the successful growth of the company."

More About Life Magnetix, Inc.

Life Magnetix, Inc. (www.lifemagnetix.com) was founded in 2009 to commercialize Asynchronous Magnetic Bead Rotation (AMBR) technology initially developed by Dr. McNaughton and others while he was with the University of Michigan. This platform technology has multiple potential uses, however the company is focusing its efforts on developing revolutionary products that will rapidly help physicians determine which antimicrobial is most effective in treating bacterial infections, referred to as Antimicrobial Susceptibility Testing. The company recently secured Series A funding from Arboretum Ventures (www.arboretumvc.com).

#####